Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
The value of fast diagnostics in time-critical infections
20 April 2026
Advancing earlier intervention in time‑critical infections Sepsis continues to impose a substantial global burden, with millions of cases and high mortality each year. Patients with bloodstream…
Around the World in HTA: Japan – An algorithmic approach to containing costs
14 April 2026
Japan’s health technology assessment (HTA) system uses algorithmic drug pricing and cost-effectiveness analysis to manage rising healthcare costs while maintaining universal access and innovation.
Around The World in HTAs: France – Three Core HTA Values
12 March 2026
In the latest edition of our Insights series, Around the World in HTAs, we explore the HTA system in France. A special thanks to Salah Ghabri for his valuable support to write this note.
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
Biologics: Driving innovation in the treatment of multiple myeloma Biological medicines (biologics) have transformed the treatment landscape of multiple myeloma and cancer as a whole. The…
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
Tumour-agnostic (TA) therapies represent a paradigm shift in oncology by targeting molecular alterations regardless of tumour histology.
Achieving Accelerated Patient Access to Cancer Care in Europe
3 November 2025
OHE developed the Accelerated Patient Access to Cancer Care in Europe (APACE) framework through a structured, multidisciplinary stakeholder engagement process.
The value of cell and gene therapies to the UK economy
20 October 2025
Cell and gene therapies (CGTs) are moving rapidly from specialist trials to routine care: more than thirty products are already licensed worldwide and over two thousand are in clinical development.
The broader economic benefits of COVID-19 vaccination
13 October 2025
Extending COVID-19 vaccination eligibility to working-age adults could nearly triple the benefits to national economies.
Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape
24 September 2025
Saudi Arabia’s healthcare system is undergoing major transformation under Vision 2030, reshaping regulation, funding and delivery models across the Kingdom. The introduction of a formal health technology assessment (HTA) framework and evolving reimbursement pathways are central to improving access to value-based healthcare.